Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245397 · ClinicalTrials.gov registry record · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
A Phase 1 study of Myelodysplastic Syndromes, sponsored by Syntrix Biosystems.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
- 7
- Study locations
NCT04245397 is a Phase 1 study of Myelodysplastic Syndromes that is actively recruiting participants, run by Syntrix Biosystems. The registered enrollment target is 151 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (47% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT04245397, a Phase 1 study of Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Syntrix Biosystems.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
Conditions Studied
Interventions
- DRUG Decitabine
- DRUG SX-682
Study Locations (7)
Florida
- Mayo Clinic - Jacksonville
- University of Miami - Miami
- AdventHealth Medical Group & Bone Marrow Transplant at Orlando - Orlando
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04245397
The ClinicalTrials.gov registry entry for NCT04245397 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (47% lower). The listed sponsor is Syntrix Biosystems, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Decitabine is the first listed.
NCT04245397 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Florida, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT04245397 about?
NCT04245397 is a clinical study titled "Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome". This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
What is the current status of trial NCT04245397?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2020-06-30. Estimated completion is 2029-03.
What conditions does trial NCT04245397 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT04245397?
The interventions under investigation include: Decitabine (DRUG), SX-682 (DRUG).
Who is sponsoring clinical trial NCT04245397?
This trial is sponsored by Syntrix Biosystems, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04245397 being conducted?
This trial has 7 study locations across Florida, Georgia, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.